Company Revenue

The company grew 20% in the second quarter of 2023 despite supply constraints on some of its newest products....

The company declined in the high single digits in the second quarter of 2023, but found international success with differentiated...

The company grew in the mid-single-digits in the second quarter of 2023 as improved execution and new products offset macro...

The company grew over 20% once again in the second quarter of 2023 despite staffing and volume challenges around pediatrics....

The company continued its trend of growth above 20% with exceptional performances across its joint replacement portfolio....

The company's orthopedic sales grew nearly 20% in the second quarter of 2023 as surgical procedure volumes and staffing levels...

The company grew 5% in the second quarter of 2023 as it sustained its recent run of improved orthopedic sales...

Today we released our public and private orthopedic company sales estimates along with Joint Replacement, Spine, Trauma, Sports Medicine, Orthobiologics...

The company grew in the low single digits for its 2023 fiscal year, but its expansive technology ecosystem is a...

The company's 1Q23 orthopedic sales declined slightly as Bioventus embarks upon a quarters-long turnaround....